Evidence map›Paper›PMID 35072888›Full record

ReviewAdvances in therapy2022

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.

Dominic Brittain, Peter D'Andrea, Emilie Gruen, Motoi Hosoe, Devendra Jain, Juergen Jauernig, Abhijit Pethe, Emil Scosyrev, Ana-Maria Tanase, Hanns-Christian Tillmann

Abstract readReviewVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.Handbook of experimental pharmacology · 2024
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dominic BrittainNovartis Pharma AG, Basel, Switzerland. dominic.brittain@novartis.com.
Peter D'AndreaNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Emilie GruenNovartis Pharma AG, Basel, Switzerland.
Motoi HosoeNovartis Pharma AG, Basel, Switzerland.
Devendra JainNovartis Pharma AG, Basel, Switzerland.
Juergen JauernigNovartis Pharma AG, Basel, Switzerland.
Abhijit PetheNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Emil ScosyrevNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Ana-Maria TanaseNovartis Pharma AG, Basel, Switzerland.
Hanns-Christian TillmannNovartis Institutes for Biomedical Research, Translational Medicine, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel, once-daily (o.d.), fixed-dose combination (FDC) of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF), delivered by the inhaler Breezhaler

Indexed as

AsthmaPulmonary Disease, Chronic ObstructiveAcetatesAdministration, InhalationAdrenergic beta-2 Receptor AgonistsAdultArgonBronchodilator AgentsDrug CombinationsDrug DevelopmentGlycopyrrolateHumansIndansIridiumMometasone FuroateNebulizers and VaporizersAcetatesAdrenergic beta-2 Receptor AgonistsArgonBronchodilator AgentsDrug CombinationsGlycopyrrolateindacaterolIndansIridiumMometasone FuroateQuinolonesAccelerated development strategyAsthmaDigital companionIndacaterol acetate/glycopyrronium bromide/mometasone furoateLABA/LAMA/ICSOnce dailySingle inhaler

Identifiers

PMID35072888
PMCPMC9122880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.